Quick Answer
MapLight Therapeutics, Inc. reported Stockholders Equity of $458.37 million for the year ending 2025.
- MapLight Therapeutics, Inc. showed an increase of +336.7% in Stockholders Equity from 2024 to 2025.
- This data is from MapLight Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$136.00 million | Q2 2024: -$154.33 million | Q3 2024: -$172.37 million | Q1 2025: -$215.83 million | Q2 2025: -$245.06 million | Q3 2025: -$274.18 million.
- Over the full 3 years of available data (2023 to 2025), MapLight Therapeutics, Inc.'s Stockholders Equity has grown by 489.8%.
- Historical annual values: Fiscal year 2025: $458.37 million | Fiscal year 2024: -$193.63 million | Fiscal year 2023: -$117.59 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: